Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 11,225 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 11,225 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total value of $245,603.00. Following the completion of the transaction, the president owned 355,995 shares of the company’s stock, valued at $7,789,170.60. This trade represents a 3.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Arcus Biosciences Trading Down 1.2%

RCUS stock traded down $0.26 during mid-day trading on Thursday, reaching $22.02. 1,175,874 shares of the stock traded hands, compared to its average volume of 1,200,446. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $26.40. The company has a market cap of $2.38 billion, a P/E ratio of -6.40 and a beta of 0.75. The stock’s fifty day moving average is $20.82 and its 200-day moving average is $13.98.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. During the same period last year, the firm posted ($1.00) earnings per share. The firm’s quarterly revenue was down 45.8% compared to the same quarter last year. As a group, sell-side analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Institutional Investors Weigh In On Arcus Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in RCUS. Goldman Sachs Group Inc. lifted its stake in shares of Arcus Biosciences by 106.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock valued at $7,177,000 after purchasing an additional 470,755 shares during the last quarter. Geode Capital Management LLC raised its holdings in Arcus Biosciences by 14.9% during the second quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock valued at $12,995,000 after buying an additional 207,097 shares in the last quarter. Rhumbline Advisers raised its holdings in Arcus Biosciences by 14.8% during the first quarter. Rhumbline Advisers now owns 182,909 shares of the company’s stock valued at $1,436,000 after buying an additional 23,645 shares in the last quarter. Tema Etfs LLC lifted its position in shares of Arcus Biosciences by 291.2% in the second quarter. Tema Etfs LLC now owns 59,662 shares of the company’s stock worth $486,000 after buying an additional 44,411 shares during the last quarter. Finally, Woodline Partners LP raised its stake in shares of Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock valued at $40,249,000 after acquiring an additional 1,603,367 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on RCUS shares. Bank of America raised their target price on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Wedbush set a $35.00 price objective on Arcus Biosciences and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Truist Financial set a $30.00 target price on Arcus Biosciences in a report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Finally, Wells Fargo & Company boosted their price objective on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Monday, October 20th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Arcus Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $28.89.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.